Fca Suit Against Genentech Dismissed
A federal appeals court turned back a lawsuit that said Genentech concealed health risks about Avastin in seeking government approval for the cancer drug. The U.S. Third Circuit Court of Appeals said the plaintiff did not show how Genentech’s actions would have made any difference under the False Claims Act. In fact, the court said Gerasimos Petratos, the former head of analytics for the company and whistleblower in the suit, acknowledged that the government would have deemed any of the alleged violations insubsubstantial....